CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Estradiol Vaginal Insertdrug
Likely dose
Estradiol Vaginal Insert 10 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04079218
NCT04079218Phase 4Completed

The Impact of HIV on Accelerated Aging in the Female Genital Tract: a Pilot Trial of Topical Estradiol to Improve the Vaginal Microbiome and Symptoms of Vaginal Atrophy in Menopausal Women With HIV

Kerry Murphy·interventional·Posted Sep 6, 2019·Updated Mar 14, 2025

In Brief

A Phase 4 clinical trial evaluating Estradiol Vaginal Insert for HIV Infection and 8 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

During menopause, there is a decrease in a hormone estrogen, which leads to aging of the vagina. Vaginal aging includes changes in the type and amount of healthy bacteria in the vagina, inflammation and a breakdown of natural barriers that keep the vagina healthy and protected from infections. Some menopausal women develop a condition called vaginal atrophy, which causes vaginal dryness, irritation, pain with sex, and itching. We are testing whether an estradiol tablet placed inside the vagina will lead to fewer changes in the types of bacteria present in the vagina, improve vaginal atrophy symptoms and ultimately keep the vagina healthier for a longer. This is important for women with HIV as they are living longer, healthier, sexually active lives due to successful treatment with antiretrovirals.

Study Details

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedSep 6, 2019
Enrollment StartSep 1, 2020
Primary CompletionAug 9, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.8 years ago

Interventions

Estradiol Vaginal Insertdrug

Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.